Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Preliminary refractive results of the Clareon® intraocular lens: about 200 cases

Search Title by author or title

Session Details

Session Title: Presented Poster Session: FLACS & Surgical Devices

Venue: Poster Village: Pod 1

First Author: : M.Chaperon FRANCE

Co Author(s): :    H. El Chehab   A. Levron   R. Chudzinski   E. Agard   C. Dot           

Abstract Details

Purpose:

The objective of our study is to analyze the preliminary refractive results of the Clareon® IOLs in order to evaluate the A constant used in the different IOL calculation formulas.

Setting:

Cataract surgery is the most common surgical procedure performed in France with nearly one million of surgeries per year. Clareon® is a new monofocal hydrophobic acrylic IOL recently marketed in Europe in May 2018 and developed by Alcon company.

Methods:

We conducted a retrospective, monocentric study on IOLs implanted consecutively between July 2017 and March 2019 by two surgeons. The power was evaluated by using the IOL Master 700® (Zeiss) for emmetropia with the SRK/T formula except for hyperopic patients where the multiformula function was preferred. The preoperative A constant used was 119.1, as recommended previously by Alcon. The postoperative refraction selected for the study was performed 1 month after surgery.

Results:

200 eyes were implanted between July 2017 and March 2019. The average age of the patients was 74 years. The mean uncorrected visual acuity (UCVA) was 0,85, the median was 0,95. Almost half of the patients (47%) had an UCVA superior to 10/10 and ¾ (73%) superior to 0,8. The mean post-operative sphere was +0.28D +/- 0.3, the median was +0.25D. The optimized A constant was thus evaluated as 119.3. No YAG capsulotomy was performed during the first year. Analysis of the transparency of Clareon® did not reveal any significant glistering (grade 0) for 100% of patients.

Conclusions:

Although the refractive results are excellent, the Clareon® IOL requires a slight optimization of its A constant near 119.3 in our study. This should be confirmed by ULIB soon. The tolerance during the first 1 year is excellent as well as the transparency of this new IOL.

Financial Disclosure:

... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous